AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
AbCellera (Nasdaq: ABCL) will participate in multiple investor conferences in November and December 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
- Truist Securities BioPharma Symposium, November 6, 2025
- Stifel Healthcare Conference, November 11-13, 2025
- Jefferies Global Healthcare Conference, November 18-20, 2025
- Piper Sandler 37th Annual Healthcare Conference, December 2-4, 2025
Visit AbCellera's Investor Relations website for additional information.
About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women’s health, immunology, and oncology. For more information, please visit www.abcellera.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251007123988/en/
Inquiries
Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774
Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005
Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116
Source: AbCellera Biologics Inc.